Overview

• In a global Phase 3 trial, mRNA-1010 delivered 26.6% higher efficacy against influenza overall in adults 50 and older, with a 27.4% gain in those 65 and above.
• The vaccine uses the same mRNA platform as Moderna’s COVID-19 shot and exhibited a safety profile comparable to standard-dose flu vaccines.
• Last season’s US flu hospitalizations reached a 15-year high, underscoring the need for more effective immunization options.
• Moderna intends to share full efficacy and safety data at an upcoming medical conference and in a peer-reviewed journal.
• The company has initiated discussions with the FDA and other regulators on potential approval pathways ahead of the next flu season.